<DOC>
	<DOCNO>NCT00268385</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together temozolomide treat patient malignant glioma . Drugs use chemotherapy , vorinostat temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may also stop growth tumor cell block enzymes need cell growth . Vorinostat may help temozolomide work well make tumor cell sensitive drug . Giving vorinostat together temozolomide may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Temozolomide Treating Patients With Malignant Gliomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) vorinostat ( suberoylanilide hydroxamic acid [ SAHA ] ) combination temozolomide patient malignant glioma . II . To characterize safety profile vorinostat ( SAHA ) combination temozolomide . SECONDARY OBJECTIVES : I . To characterize pharmacokinetics vorinostat ( SAHA ) combination temozolomide . II . To determine efficacy vorinostat ( SAHA ) combination temozolomide measure objective response . TERTIARY OBJECTIVES : I . To explore association response treatment molecular phenotype tumor . II . To assess effect vorinostat ( SAHA ) histone acetylation status peripheral mononuclear cell . OUTLINE : This 2-part , dose-escalation study vorinostat . PART I : Patients receive vorinostat orally ( PO ) ( QD ) twice daily ( BID ) day 1-7 15-21 OR QD BID day 1-7 . Patients also receive temozolomide PO QD day 1-5 . Treatment repeat every 28 day 13 course absence disease progression unacceptable toxicity . Beginning course 2 , patient may receive high dose temozolomide . Treatment may continue beyond 13 course discretion investigator . PART II : Patients receive vorinostat temozolomide part 1* . [ Note : *Beginning course 2 , patient receive high dose temozolomide . ] After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients histologically prove intracranial malignant glioma eligible protocol ; malignant glioma include glioblastoma multiforme ( GBM ) , gliosarcoma ( GS ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant astrocytoma NOS ( otherwise specify ) ; patient eligible original histology lowgrade glioma subsequent histological diagnosis malignant glioma make All patient must sign informed consent indicate aware investigational nature study ; patient must sign authorization release protect health information ; patient must register Adult Brain Tumor Consortium ( ABTC ) Central Office database prior treatment study drug Life expectancy &gt; 8 week Karnofsky performance status &gt; = 60 White blood cell ( WBC ) &gt; = 3,000/mm^3 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 10 g/dL ; eligibility level hemoglobin may reach transfusion Serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; 2 time ULN If liver function test institutional upper limit normal &lt; 2 time institutional upper limit normal , decision initiate temozolomide treatment carefully consider benefit risk individual patient Creatinine &lt; 1.5 mg/dL A scan performed within 14 day prior registration steroid dose stable least 5 day ; steroid dose increase date image registration new baseline magnetic resonance ( MR ) /computed tomography ( CT ) require ; type scan , i.e. , magnetic resonance imaging ( MRI ) CT must use throughout period protocol treatment tumor measurement Patients must interval great equal 3 week ( 21 ) day completion radiation therapy study entry Women childbearing potential must negative betahuman chorionic gonadotropin ( HCG ) pregnancy test document within 7 day prior registration ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration participation study Patients must willing participate pharmacokinetic study ELIGIBILITY CRITERIA SPECIFIC FOR PATIENTS IN PART I OF THE STUDY Patients either stable disease radiation therapy progression eligible ( except progress temozolomide ; patient receive prior treatment temozolomide stable disease eligible Patients recurrent disease may treatment number prior relapse ; relapse define progression follow initial therapy ( i.e . radiation +/ chemo use initial therapy ) Patients must recover toxic effect prior therapy : 28 day investigational agent , 28 day prior cytotoxic therapy except 23 day last dose temozolomide patient take standard 5 day every 28 day regimen temozolomide , 14 day vincristine , 42 day nitrosoureas , 21 day procarbazine administration , 7 day noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) ; question relate definition noncytotoxic agent direct study chair Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : They recover effect surgery Residual disease follow resection mandate eligibility study ; best ass extent residual disease postoperatively , CT/MRI do later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day prior registration ; 96hour scan 14 day registration , scan need repeat ; steroid dose increase date imaging registration , new baseline MRI/CT require stable steroid dosage least 5 day Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis base upon either positron emission tomography ( PET ) thallium scanning , MR spectroscopy surgical documentation disease ELIGIBILITY CRITERIA SPECIFIC FOR PATIENTS IN PART II OF THE STUDY Only patient stable disease radiation therapy eligible part 2 study ; patient recurrent disease ineligible The prior therapy permit patient part 2 study concomitant temozolomide radiation therapy radiation therapy alone ; patient stable adjuvant temozolomide may also participate Patients recurrent disease prior chemotherapy ( except concurrent adjuvant temozolomide ) include part study Patients progress temozolomide ineligible Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy ; patient history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible Patients must active infection serious intercurrent medical illness Pregnant woman exclude study ; breastfeed discontinue mother treat vorinostat ( SAHA ) ; potential risk may also apply temozolomide Patients must disease obscure toxicity dangerously alter drug metabolism Patients know human immunodeficiency virus ( HIV ) positive receive combination antiretroviral therapy ineligible Patients may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition vorinostat ( SAHA ) agent use study Patients take valproic acid ( another histone deacetylase inhibitor ) least 2 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>